Blinatumomab, sold under the brand name Blincyto, and known informally as blina, is a biopharmaceutical medication used as a second-line treatment for...
12 KB (995 words) - 17:38, 19 June 2024
Bi-specific T-cell engager (section Blinatumomab)
and clinical trials to assess their therapeutic efficacy and safety. Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The...
9 KB (1,472 words) - 21:30, 9 September 2024
Amgen's next-generation biomanufacturing facility in Singapore. Blincyto (blinatumomab) was approved by the FDA in December of that year. Amgen's Thousand Oaks...
96 KB (7,758 words) - 18:19, 12 September 2024
in immunotherapy, particularly the use of monoclonal antibodies like blinatumomab and inotuzumab ozogamicin, which target specific cancer cells and are...
78 KB (7,755 words) - 17:38, 17 September 2024
(Bristol-Myers Squibb) bleomycin (INN) Bleph-10 (Allergan) Blephamide (Allergan) blinatumomab (USAN, INN) Blis-To-Sol (Oakhurst Company) Blocadren (Merck) blonanserin...
7 KB (386 words) - 17:54, 5 October 2024
allergic reactions in humans. An example of a murine monoclonal antibody is blinatumomab, which is used to treat acute lymphoblastic leukemia. Chimeric monoclonal...
20 KB (2,374 words) - 01:40, 6 September 2024
clinical trials. The first bispecific antibody to gain regulatory approval, blinatumomab, targets CD19 on B cells and CD3 on T cells, leading to the activation...
29 KB (3,349 words) - 19:04, 30 July 2024
cell carcinoma Bleselumab mab human CD40 organ transplant rejection Blinatumomab Blincyto BiTE mouse CD19 Y pre-B Acute lymphoblastic leukemia (ALL) (CD19+)...
136 KB (4,020 words) - 06:13, 27 September 2024
Ipilimumab L01FX05 Brentuximab vedotin L01FX06 Dinutuximab beta L01FX07 Blinatumomab L01FX08 Elotuzumab L01FX09 Mogamulizumab L01FX10 Olaratumab L01FX11 Bermekimab...
12 KB (877 words) - 15:36, 25 January 2024
fibrosis Nintedanib Boehringer Ingelheim idiopathic pulmonary fibrosis Blinatumomab Amgen acute lymphoblastic leukemia Ombitasvir/paritaprevir/ritonavir/dasabuvir...
34 KB (180 words) - 22:09, 8 April 2024
duvelisib, ublituximab, zanubrutinib, obinutuzumab, olatuzumab, and blinatumomab) which are used to treat CLL/SLL and/or DLBCL-not RT have been added...
37 KB (4,783 words) - 14:57, 23 February 2024
B Prevent recurrence of Clostridium difficile infection 761046 Link blinatumomab Blincyto Amgen 12/3/2014 intravenous mouse, bispecific CD19 Precursor...
57 KB (4,072 words) - 11:12, 5 August 2024
(+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab...
12 KB (808 words) - 05:25, 15 September 2024
(+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab...
12 KB (758 words) - 23:46, 14 March 2024
Kantarjian; Anthony Stein; Adele K Fielding; et al. (1 March 2017). "Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia". The New...
8 KB (906 words) - 06:37, 23 April 2024
Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab...
5 KB (368 words) - 15:29, 21 August 2024
antibody that binds CD40; Siglec-3 a monoclonal antibody that binds CD33; blinatumomab, a monoclonal antibody that binds both CD3 and CD19; chimeric antigen...
22 KB (2,669 words) - 05:05, 4 January 2024
nervous system. Baeuerle lead the development of BiTE antibody Blincyto® (blinatumomab; AMG 103) which is approved by the US FDA for treatment of relapsed/refractory...
10 KB (888 words) - 00:20, 30 May 2024
Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab...
4 KB (241 words) - 13:42, 14 July 2024
Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab...
3 KB (129 words) - 01:04, 19 July 2023